journal
MENU ▼
Read by QxMD icon Read
search

Lancet Infectious Diseases

journal
https://read.qxmd.com/read/31101501/correction-to-lancet-infect-dis-2019-19-344-45
#1
(no author information available yet)
No abstract text is available yet for this article.
May 14, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31079949/measles-resurgence-in-the-usa-how-international-travel-compounds-vaccine-resistance
#2
Sahotra Sarkar, Aleksa Zlojutro, Kamran Khan, Lauren Gardner
No abstract text is available yet for this article.
May 9, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31079948/a-step-further-in-a-vaccine-for-escherichia-coli
#3
Florian Me Wagenlehner, Kurt G Naber
No abstract text is available yet for this article.
May 9, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31079947/safety-and-immunogenicity-of-a-vaccine-for-extra-intestinal-pathogenic-escherichia-coli-estella-a-phase-2-randomised-controlled-trial
#4
Robert W Frenck, John Ervin, Laurence Chu, Darren Abbanat, Bart Spiessens, Oscar Go, Wouter Haazen, Germie van den Dobbelsteen, Jan Poolman, Stefan Thoelen, Patricia Ibarra de Palacios
BACKGROUND: ExPEC4V (JNJ-63871860) is a bioconjugate vaccine, containing O-antigens from Escherichia coli serotypes O1A, O2, O6A, and O25B, developed for the prevention of invasive extra-intestinal pathogenic E coli (ExPEC) disease. We aimed to assess safety, reactogenicity, and immunogenicity of ExPEC4V in healthy adults. METHODS: In this phase 2 randomised, double-blind placebo-controlled study, we recruited healthy adults (≥18 years with a body-mass index of 35 kg/m2 or less) between Nov 16, 2015, and Aug 8, 2017, and randomly assigned them to receive a single dose of ExPEC4V (antigen O1A:O2:O6A:O25B content 4:4:4:4 μg [group 1]; 4:4:4:8 μg [group 2], 8:8:8:8 μg [group 3], 8:8:8:16 μg [group 4], or 16:16:16:16 μg [group 5]) or placebo...
May 9, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31060930/dengvaxia-researcher-charged
#5
Patralekha Chatterjee
No abstract text is available yet for this article.
May 3, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31056427/cal02-a-novel-antitoxin-liposomal-agent-in-severe-pneumococcal-pneumonia-a-first-in-human-double-blind-placebo-controlled-randomised-trial
#6
Pierre-François Laterre, Gwenhael Colin, Pierre-François Dequin, Thierry Dugernier, Thierry Boulain, Samareh Azeredo da Silveira, Frédéric Lajaunias, Antonio Perez, Bruno François
BACKGROUND: Severe community-acquired pneumonia caused by Streptococcus pneumoniae is associated with high morbidity and mortality rates. CAL02, a novel antitoxin agent with an unprecedented mode of action, consists of liposomes that capture bacterial toxins known to dysregulate inflammation, cause organ damage, and impede immune defence. We aimed to assess the safety of CAL02 as an add-on therapy to antibiotics. METHODS: This randomised, double-blind, multicentre, placebo-controlled trial was done in ten intensive care units (ICUs) in France and Belgium (but only six units enrolled patients), in patients with severe community-acquired pneumococcal pneumonia who required ICU admission and had been identified as being infected with S pneumoniae...
May 2, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31056426/one-step-closer-to-precision-medicine-for-infectious-diseases
#7
Mathias W Pletz, Michael Bauer, Axel A Brakhage
No abstract text is available yet for this article.
May 2, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31053494/correction-to-lancet-infect-dis-2019-19-449
#8
(no author information available yet)
No abstract text is available yet for this article.
April 30, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31053493/standing-on-the-shoulders-of-giants-two-centuries-of-struggle-against-meningococcal-disease
#9
REVIEW
Pere Domingo, Virginia Pomar, Albert Mauri, Nicolau Barquet
Meningococcal disease was first clinically characterised by Gaspard Vieusseux in 1805, and its causative agent was identified by Anton Weichselbaum in 1887, who named it Diplococcus intracellularis menigitidis. From the beginning, the disease was dreaded because of its epidemic nature, predilection for previously healthy children and adolescents, and high mortality. In the last decade of the 19th century, the concept of serum therapy for toxin-related bacterial diseases was identified. This concept was applied to meningococcal disease therapy, in an independent way, by Wilhelm Kolle, August von Wasserman, and Georg Jochmann in Germany, and Simon Flexner in the USA, resulting in the first successful approach for the treatment of meningococcal disease...
April 30, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31053492/microbial-evolutionary-medicine-from-theory-to-clinical-practice
#10
REVIEW
Sandra B Andersen, B Jesse Shapiro, Christina Vandenbroucke-Grauls, Marjon G J de Vos
Medicine and clinical microbiology have traditionally attempted to identify and eliminate the agents that cause disease. However, this traditional approach is becoming inadequate for dealing with a changing disease landscape. Major challenges to human health are non-communicable chronic diseases, often driven by altered immunity and inflammation, and communicable infections from agents which harbour antibiotic resistance. This Review focuses on the so-called evolutionary medicine framework, to study how microbial communities influence human health...
April 30, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31047852/effect-of-carbapenem-resistance-on-outcomes-of-bloodstream-infection-caused-by-enterobacteriaceae-in-low-income-and-middle-income-countries-panorama-a-multinational-prospective-cohort-study
#11
Andrew J Stewardson, Kalisvar Marimuthu, Sharmila Sengupta, Arthur Allignol, Maisra El-Bouseary, Maria J Carvalho, Brekhna Hassan, Monica A Delgado-Ramirez, Anita Arora, Ruchika Bagga, Alex K Owusu-Ofori, Joseph O Ovosi, Shamsudin Aliyu, Hala Saad, Souha S Kanj, Basudha Khanal, Balkrishna Bhattarai, Samir K Saha, Jamal Uddin, Purabi Barman, Latika Sharma, Tarek El-Banna, Rabaab Zahra, Mansab Ali Saleemi, Amarjeet Kaur, Kenneth Iregbu, Nkolika Sc Uwaezuoke, Pierre Abi Hanna, Rita Feghali, Ana L Correa, Maria I Munera, Thi Anh Thu Le, Thi Thanh Nga Tran, Chimanjita Phukan, Chiranjita Phukan, Sandra L Valderrama-Beltrán, Carlos Alvarez-Moreno, Timothy R Walsh, Stephan Harbarth
BACKGROUND: Low-income and middle-income countries (LMICs) are under-represented in reports on the burden of antimicrobial resistance. We aimed to quantify the clinical effect of carbapenem resistance on mortality and length of hospital stay among inpatients in LMICs with a bloodstream infection due to Enterobacteriaceae. METHODS: The PANORAMA study was a multinational prospective cohort study at tertiary hospitals in Bangladesh, Colombia, Egypt, Ghana, India, Lebanon, Nepal, Nigeria, Pakistan, and Vietnam, recruiting consecutively diagnosed patients with carbapenem-susceptible Enterobacteriaceae (CSE) and carbapenem-resistant Entero-bacteriaceae (CRE) bloodstream infections...
April 29, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31047851/carbapenem-resistant-enterobacteriaceae-global-action-required
#12
Federico Perez, Robert A Bonomo
No abstract text is available yet for this article.
April 29, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31036512/point-of-care-tests-to-reduce-the-burden-of-sexually-transmitted-infections
#13
Rosanna Wai Wan Peeling, David Mabey
No abstract text is available yet for this article.
April 26, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31036511/tracking-spending-on-malaria-by-source-in-106-countries-2000-16-an-economic-modelling-study
#14
Annie Haakenstad, Anton Connor Harle, Golsum Tsakalos, Angela E Micah, Tianchan Tao, Mina Anjomshoa, Jessica Cohen, Nancy Fullman, Simon I Hay, Tomislav Mestrovic, Shafiu Mohammed, Seyyed Meysam Mousavi, Molly R Nixon, David Pigott, Khanh Tran, Christopher J L Murray, Joseph L Dieleman
BACKGROUND: Sustaining achievements in malaria control and making progress toward malaria elimination requires coordinated funding. We estimated domestic malaria spending by source in 106 countries that were malaria-endemic in 2000-16 or became malaria-free after 2000. METHODS: We collected 36 038 datapoints reporting government, out-of-pocket (OOP), and prepaid private malaria spending, as well as malaria treatment-seeking, costs of patient care, and drug prices...
April 26, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31031173/challenges-in-tacking-global-malaria-spending
#15
Joey Brooke, Devi Sridhar
No abstract text is available yet for this article.
April 25, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31031172/targeted-point-of-care-testing-compared-with-syndromic-management-of-urogenital-infections-in-women-wish-a-cross-sectional-screening-and-diagnostic-accuracy-study
#16
Marijn C Verwijs, Stephen K Agaba, Jean-Claude Sumanyi, Marie Michele Umulisa, Lambert Mwambarangwe, Viateur Musengamana, Mireille Uwineza, Vicky Cuylaerts, Tania Crucitti, Vicky Jespers, Janneke H H M van de Wijgert
BACKGROUND: Sexually transmitted and urogenital infections are typically managed by WHO-recommended syndromic algorithms in resource-poor countries, and presumptively in Europe. However, algorithms for vaginal discharge and lower abdominal pain perform poorly in women. The women's improvement of sexual and reproductive health (WISH) study in Kigali, Rwanda, sought to improve case-finding and infection management in women by introducing point-of-care tests. The main aim was to compare the performance of the WISH algorithms and the WHO vaginal discharge and lower abdominal pain algorithms with gold standard testing...
April 25, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31031171/potential-of-marine-natural-products-against-drug-resistant-bacterial-infections
#17
REVIEW
Miaomiao Liu, Ebaa M El-Hossary, Tobias A Oelschlaeger, Mohamed S Donia, Ronald J Quinn, Usama Ramadan Abdelmohsen
Natural products have been a rich source of compounds with structural and chemical diversity for drug discovery. However, antibiotic resistance in bacteria has been reported for nearly every antibiotic once it is used in clinical practice. In the past decade, pharmaceutical companies have reduced their natural product discovery projects because of challenges, such as high costs, low return rates, and high rediscovery rates. The largely unexplored marine environment harbours substantial diversity and is a large resource to discover novel compounds with novel modes of action, which is essential for the treatment of drug-resistant bacterial infections...
April 25, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31006605/the-uk-s-pandemic-influenza-research-portfolio-a-model-for-future-research-on-emerging-infections
#18
REVIEW
Colin R Simpson, Dan Beever, Kirsty Challen, Daniela De Angelis, Ellen Fragaszy, Steve Goodacre, Andrew Hayward, Wei Shen Lim, G James Rubin, Malcolm G Semple, Marian Knight
The 2009 influenza A H1N1 pandemic was responsible for considerable global morbidity and mortality. In 2009, several research studies in the UK were rapidly funded and activated for clinical and public health actions. However, some studies were too late for their results to have an early and substantial effect on clinical care, because of the time required to call for research proposals, assess, fund, and set up the projects. In recognition of these inherent delays, a portfolio of projects was funded by the National Institute for Health Research in 2012...
April 18, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31005559/risk-factors-associated-with-revision-for-prosthetic-joint-infection-following-knee-replacement-an-observational-cohort-study-from-england-and-wales
#19
Erik Lenguerrand, Michael R Whitehouse, Andrew D Beswick, Setor K Kunutsor, Pedro Foguet, Martyn Porter, Ashley W Blom
BACKGROUND: Prosthetic joint infection is a devastating complication of knee replacement. The risk of developing a prosthetic joint infection is affected by patient, surgical, and health-care system factors. Existing evidence is limited by heterogeneity in populations studied, short follow-up, inadequate power, and does not differentiate early prosthetic joint infection, most likely related to the intervention, from late infection, more likely to occur due to haematogenous bacterial spread...
April 17, 2019: Lancet Infectious Diseases
https://read.qxmd.com/read/31005558/still-fighting-prosthetic-joint-infection-after-knee-replacement
#20
Thorsten Gehrke, Christian Lausmann, Mustafa Citak
No abstract text is available yet for this article.
April 17, 2019: Lancet Infectious Diseases
journal
journal
20187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"